These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 21295474

  • 1. 3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor.
    Scott DA, Dakin LA, Del Valle DJ, Diebold RB, Drew L, Gero TW, Ogoe CA, Omer CA, Repik G, Thakur K, Ye Q, Zheng X.
    Bioorg Med Chem Lett; 2011 Mar 01; 21(5):1382-4. PubMed ID: 21295474
    [Abstract] [Full Text] [Related]

  • 2. Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507.
    Scott DA, Dakin LA, Daly K, Del Valle DJ, Diebold RB, Drew L, Ezhuthachan J, Gero TW, Ogoe CA, Omer CA, Redmond SP, Repik G, Thakur K, Ye Q, Zheng X.
    Bioorg Med Chem Lett; 2013 Aug 15; 23(16):4591-6. PubMed ID: 23842474
    [Abstract] [Full Text] [Related]

  • 3. Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase.
    Scott DA, Balliet CL, Cook DJ, Davies AM, Gero TW, Omer CA, Poondru S, Theoclitou ME, Tyurin B, Zinda MJ.
    Bioorg Med Chem Lett; 2009 Feb 01; 19(3):697-700. PubMed ID: 19112018
    [Abstract] [Full Text] [Related]

  • 4. A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
    Shen HC, Ding FX, Deng Q, Xu S, Tong X, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Roy S, Zhang B, Tata JR, Berger JP, Colletti SL.
    Bioorg Med Chem Lett; 2009 Oct 01; 19(19):5716-21. PubMed ID: 19700315
    [Abstract] [Full Text] [Related]

  • 5. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
    Wilson KJ, Illig CR, Chen J, Wall MJ, Ballentine SK, DesJarlais RL, Chen Y, Schubert C, Donatelli R, Petrounia I, Crysler CS, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Meegalla SK.
    Bioorg Med Chem Lett; 2010 Jul 01; 20(13):3925-9. PubMed ID: 20570147
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.
    Illig CR, Manthey CL, Meegalla SK, Wall MJ, Chen J, Wilson KJ, DesJarlais RL, Ballentine SK, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE.
    Bioorg Med Chem Lett; 2013 Dec 01; 23(23):6363-9. PubMed ID: 24138939
    [Abstract] [Full Text] [Related]

  • 7. Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.
    Scott DA, Aquila BM, Bebernitz GA, Cook DJ, Dakin LA, Deegan TL, Hattersley MM, Ioannidis S, Lyne PD, Omer CA, Ye M, Zheng X.
    Bioorg Med Chem Lett; 2008 Sep 01; 18(17):4794-7. PubMed ID: 18694641
    [Abstract] [Full Text] [Related]

  • 8. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.
    Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reitz BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1543-7. PubMed ID: 20137931
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
    Wrobleski ST, Lin S, Hynes J, Wu H, Pitt S, Shen DR, Zhang R, Gillooly KM, Shuster DJ, McIntyre KW, Doweyko AM, Kish KF, Tredup JA, Duke GJ, Sack JS, McKinnon M, Dodd J, Barrish JC, Schieven GL, Leftheris K.
    Bioorg Med Chem Lett; 2008 Apr 15; 18(8):2739-44. PubMed ID: 18364256
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
    Zhang N, Wu B, Boschelli DH, Golas JM, Boschelli F.
    Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5071-4. PubMed ID: 19632113
    [Abstract] [Full Text] [Related]

  • 18. 3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile.
    Scott DA, Bell KJ, Campbell CT, Cook DJ, Dakin LA, Del Valle DJ, Drew L, Gero TW, Hattersley MM, Omer CA, Tyurin B, Zheng X.
    Bioorg Med Chem Lett; 2009 Feb 01; 19(3):701-5. PubMed ID: 19114305
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors.
    Wall MJ, Chen J, Meegalla S, Ballentine SK, Wilson KJ, DesJarlais RL, Schubert C, Chaikin MA, Crysler C, Petrounia IP, Donatelli RR, Yurkow EJ, Boczon L, Mazzulla M, Player MR, Patch RJ, Manthey CL, Molloy C, Tomczuk B, Illig CR.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2097-102. PubMed ID: 18289848
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.